Pancreatic ductal adenocarcinoma (PDA) is characterized by immune tolerance and
immunotherapeutic resistance. We discovered upregulation of receptor-interacting
serine/threonine protein kinase 1 (RIP1) in tumor-associated macrophages (TAMs) in PDA.
To study its role in oncogenic progression, we developed a selective small-molecule RIP1
inhibitor with high in vivo exposure. Targeting RIP1 reprogrammed TAMs toward an MHCII
hi TNFα+ IFNγ+ immunogenic phenotype in a STAT1-dependent manner. RIP1 inhibition in …

(Cancer Cell 34, 757–774. e1–e7; November 12, 2018) We reported that RIP1 kinase
signaling in macrophages promotes suppression of anti-tumor immunity in pancreatic
cancer. During preparation of the manuscript, we submitted an incorrect version of Figure 1H
in which one slide from the 3 month ''RIP1i''group was inadvertently omitted from the
analysis in the bar graph. We have included here a corrected version of Figure 1. In the
original article, the legend for Figure 1H incorrectly states n= 8. The correct n values are n= 6 …